Skip to content

Advanced BioMedical Technologies, Inc.: 10-Q filed 2019-04-01

What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2019-04-01 (fiscal Q1 2019): 26 published measures, 56 facts as tagged in accession 0001493152-19-004448.

This filing

Form
10-Q (quarterly report)
Filed
2019-04-01
Fiscal period
fiscal Q1 2019
Accession
0001493152-19-004448 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-01-31189,574USD
At 2018-10-31142,404USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-01-31-6,080,031USD
At 2018-10-31-5,619,012USD
At 2017-10-31-4,995,027USD
At 2016-10-31-4,362,295USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-01-3116,945USD
At 2018-10-316,860USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-252,523USD92
2017-11-01 to 2018-10-31-953,320USD365
2017-11-01 to 2018-01-31-222,543USD92
2016-11-01 to 2017-10-31-691,600USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-199,767USD92
2017-11-01 to 2018-01-31-228,331USD92

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-11-01 to 2019-01-317,968USD92
2017-11-01 to 2018-01-314,457USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-11-01 to 2019-01-31234,622USD92
2017-11-01 to 2018-01-31243,455USD92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-25,043USD92
2017-11-01 to 2018-01-31-4,457USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-01-31-8,885,141USD
At 2018-10-31-8,632,618USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-01-31110,166USD
At 2018-10-31102,895USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-169,909USD92
2017-11-01 to 2018-01-31-139,621USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-01-3161,892USD
At 2018-10-3139,509USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-01-316,269,605USD
At 2018-10-315,761,416USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-11-01 to 2019-01-31169,909USD92
2017-11-01 to 2018-01-31139,621USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-11-01 to 2019-01-3116,979USD92
2017-11-01 to 2018-01-3115,770USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-01-3169,624,850shares
At 2018-10-3169,624,850shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2019-01-3161,083USD
At 2018-10-31272,727USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-01-31550,368USD
At 2018-10-31521,120USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-01-31440,202USD
At 2018-10-31418,225USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-01-3144,947USD
At 2018-10-3132,649USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-252,523USD92
2017-11-01 to 2018-01-31-222,543USD92

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-252,523USD92
2017-11-01 to 2018-01-31-222,543USD92

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-11-01 to 2019-01-31-464,167USD92
2017-11-01 to 2018-01-31-477,961USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-11-01 to 2019-01-31147,930USD92
2017-11-01 to 2018-01-31121,672USD92

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-11-01 to 2019-01-315,000USD92
2017-11-01 to 2018-01-312,179USD92

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-11-01 to 2019-01-3110USD92
2017-11-01 to 2018-01-317USD92

Inspect the source

Entity
Advanced BioMedical Technologies, Inc. / CIK 0001385799
Captured
SEC response SHA-256
1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))